摘要
通过回顾阿瑞匹坦临床应用的文献报道,为合理用药提供理论参考。阿瑞匹坦在控制高致吐风险和中致吐风险的肿瘤化疗所致恶心呕吐方面有较好的疗效。其常见不良反应涉及消化系统和神经系统,可能增加严重感染的发生率。阿瑞匹坦和主要经过CYP2C9酶和CYP3A4酶代谢,尤其是治疗窗较窄的药物联用时,临床医生及临床药师应重视药物之间的相互作用,对患者进行用药监测。
To provide theoretical reference for rational medication,literature reports on clinical application of aprepitant were reviewed.Aprepitant is effective in treating nausea and vomiting caused by tumor chemotherapy with high and moderate risk of vomiting.The common adverse reactions involve digestive system and nervous system,and they may increase the incidence of serious infection.When aprepitant is used in combination with drugs which are mainly metabolized by CYP2C9 enzyme and CYP3A4 enzyme,especially those with narrow therapeutic window,clinicians and clinical pharmacists should pay attention to the interactions among drugs and monitor the medications in patients.
作者
顾秋君
陈志高
GU Qiujun;CHEN Zhigao(Pharmacy Department,Jiangyin People's Hospital,Jiangsu,Jiangyin 214400,China)
出处
《中国医药科学》
2020年第19期48-51,共4页
China Medicine And Pharmacy
基金
江苏省药学会-奥赛康医院药学基金科研课题(A201919)。
